The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

OBJECTIVE: To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. METHODS: In this international, 6-month, open-label trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, M, Pritchard, C, Huffstutter, J E, Rodriguez-Valverde, V, Durez, P, Zhou, X, Li, T, Bahrt, K, Kelly, S, Le Bars, M, Genovese, M C
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756956/
https://www.ncbi.nlm.nih.gov/pubmed/19074911
http://dx.doi.org/10.1136/ard.2008.099218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756956/
https://www.ncbi.nlm.nih.gov/pubmed/19074911
http://dx.doi.org/10.1136/ard.2008.099218

Ejemplares similares